Compare RUN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | LIVN |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2015 | 2015 |
| Metric | RUN | LIVN |
|---|---|---|
| Price | $12.47 | $64.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | $18.80 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 7.6M | 654.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | N/A |
| Revenue This Year | $2.81 | $9.79 |
| Revenue Next Year | $4.54 | $6.63 |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | ★ 12.97 | N/A |
| 52 Week Low | $5.38 | $35.00 |
| 52 Week High | $22.44 | $71.58 |
| Indicator | RUN | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 52.48 |
| Support Level | $12.01 | $61.63 |
| Resistance Level | $13.57 | $65.61 |
| Average True Range (ATR) | 0.69 | 1.95 |
| MACD | 0.01 | 0.20 |
| Stochastic Oscillator | 24.75 | 50.53 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.